Abstract
Murai H, Suzuki S, Hasebe M, et al. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord 2021; 14: 1–12. DOI: 10.1177/1687814018772718
In the above article:
On page 5, first column, third paragraph, sixth line, the correct details are (overall 76.9% (20/26)) at 26 weeks and not (overall 76.9% (920/26)) at 26 weeks.
The correct link in the data availability statement (15th line) is https://alexion.com/our-research/research-and-development
The online version has also been updated.